Sengupta S (ed.)
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Red Fox Peptides sources pharmaceutical-grade GHK-Cu with full COA documentation available
In preclinical models, this translates to measurably faster healing of tendons, ligaments, muscles, and GI tissue
There are some possible GHK-Cu side effects worth watching out for
GHK-Cu Topical Peptide GHK-Cu topical peptide is a copper tripeptide that has been extensively studied for its effects on skin health